Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DW-MSC in COVID-19 Patients
NCT04535856Phase 1Completed
- Sponsor
- INA-RESPOND
- Start
- Nov 2020
- Primary completion
- Jan 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DW-MSC in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by INA-RESPOND. Primary endpoint: Treatment-Emergent Adverse Events at 28 days. Started Nov 2020; status: completed.
02
Drugs
DW-MSC
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04535856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04535856.